Last reviewed · How we verify
FF/VI (100/25) mcg
FF/VI (100/25) mcg is a Inhaled corticosteroid/long-acting beta-2 agonist combination Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.
FF/VI is a combination of fluticasone furoate (inhaled corticosteroid) and vilanterol (long-acting beta-2 agonist) that reduces airway inflammation and improves bronchodilation in respiratory disease.
FF/VI is a combination of fluticasone furoate (inhaled corticosteroid) and vilanterol (long-acting beta-2 agonist) that reduces airway inflammation and improves bronchodilation in respiratory disease. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | FF/VI (100/25) mcg |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor (fluticasone furoate); Beta-2 adrenergic receptor (vilanterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone furoate acts as a potent inhaled corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors. Vilanterol is a long-acting beta-2 agonist that stimulates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained respiratory symptom control.
Approved indications
- Asthma maintenance treatment
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness/anxiety
Key clinical trials
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
- Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FF/VI (100/25) mcg CI brief — competitive landscape report
- FF/VI (100/25) mcg updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about FF/VI (100/25) mcg
What is FF/VI (100/25) mcg?
How does FF/VI (100/25) mcg work?
What is FF/VI (100/25) mcg used for?
Who makes FF/VI (100/25) mcg?
What drug class is FF/VI (100/25) mcg in?
What development phase is FF/VI (100/25) mcg in?
What are the side effects of FF/VI (100/25) mcg?
What does FF/VI (100/25) mcg target?
Related
- Drug class: All Inhaled corticosteroid/long-acting beta-2 agonist combination drugs
- Target: All drugs targeting Glucocorticoid receptor (fluticasone furoate); Beta-2 adrenergic receptor (vilanterol)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Asthma maintenance treatment
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Compare: FF/VI (100/25) mcg vs similar drugs
- Pricing: FF/VI (100/25) mcg cost, discount & access